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Evolutionary Pathways to Persistence of 
Highly Fit and Resistant Hepatitis C Virus 
Protease Inhibitor Escape Variants
Sanne Brun Jensen,1* Ulrik Fahnøe,1* Long V. Pham,1 Stéphanie Brigitte Nelly Serre,1 Qi Tang,1 Lubna Ghanem,1  
Martin Schou Pedersen,1,2 Santseharay Ramirez,1 Daryl Humes,1 Anne Finne Pihl,1 Jonathan Filskov,1 Christina Søhoel Sølund,1,3 
Julia Dietz,4 Slim Fourati,5 Jean-Michel Pawlotsky,5 Christoph Sarrazin,4,6 Nina Weis,3,7 Kristian Schønning,2,7 Henrik Krarup,8  
Jens Bukh ,1 and Judith Margarete Gottwein 1
Protease inhibitors (PIs) are important components of treatment regimens for patients with chronic hepatitis C virus 
(HCV) infection. However, emergence and persistence of antiviral resistance could reduce their efficacy. Thus, 
defining resistance determinants is highly relevant for efforts to control HCV. Here, we investigated patterns of PI 
resistance–associated substitutions (RASs) for the major HCV genotypes and viral determinants for persistence of 
key RASs. We identified protease position 156 as a RAS hotspot for genotype 1-4, but not 5 and 6, escape variants 
by resistance profiling using PIs grazoprevir and paritaprevir in infectious cell culture systems. However, except for 
genotype 3, engineered 156-RASs were not maintained. For genotypes 1 and 2, persistence of 156-RASs depended 
on genome-wide substitution networks, co-selected under continued PI treatment and identified by next-generation 
sequencing with substitution linkage and haplotype reconstruction. Persistence of A156T for genotype 1 relied on 
compensatory substitutions increasing replication and assembly. For genotype 2, initial selection of A156V facilitated 
transition to 156L, persisting without compensatory substitutions. The developed genotype 1, 2, and 3 variants with 
persistent 156-RASs had exceptionally high fitness and resistance to grazoprevir, paritaprevir, glecaprevir, and vox-
ilaprevir. A156T dominated in genotype 1 glecaprevir and voxilaprevir escape variants, and pre-existing A156T fa-
cilitated genotype 1 escape from clinically relevant combination treatments with grazoprevir/elbasvir and glecaprevir/
pibrentasvir. In genotype 1 infected patients with treatment failure and 156-RASs, we observed genome-wide selec-
tion of substitutions under treatment. Conclusion: Comprehensive PI resistance profiling for HCV genotypes 1-6 
revealed 156-RASs as key determinants of high-level resistance across clinically relevant PIs. We obtained in vitro 
proof of concept for persistence of highly fit genotype 1-3 156-variants, which might pose a threat to clinically rel-
evant combination treatments. (Hepatology 2019;70:771-787).
Worldwide, hepatitis C virus (HCV) is esti-mated to cause at least 70 million chronic infections, with 400,000 deaths annually.(1) Genotypes 1-3 cause more than 80% of infections worldwide.(2) The development of efficient direct act-ing antivirals (DAAs) has revolutionized treatment of 
Abbreviations: aa, amino acid; DAA, direct acting antiviral; HCV, hepatitis C virus; NGS, next-generation sequencing; NS, nonstructural 
protein; NS3H, NS3 helicase; NS3P, NS3 protease; ORF, open reading frame; PI, protease inhibitor; RAS, resistance-associated substitution; 
SNP, single nucleotide polymorphism.
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chronic HCV infection.(3-5) The main DAA targets 
are the HCV nonstructural protein (NS) 3 protease 
(NS3P), the NS5A protein, and the NS5B polymerase. 
To counteract the emergence of resistance, DAAs are 
administered in combinations, and protease inhibitors 
(PIs) are important components of several DAA-based 
treatment regimens.(3-6) The PI grazoprevir in combi-
nation with the NS5A inhibitor elbasvir, as well as the 
PI paritaprevir in combination with the NS5A inhibi-
tor ombitasvir and the nonnucleosidic NS5B inhibitor 
dasabuvir, were approved for treatment of genotypes 1 
and 4.(3,4) Recently, the PI glecaprevir in combination 
with the NS5A inhibitor pibrentasvir was approved for 
treatment of genotypes 1-6. Further, the PI voxilapre-
vir in combination with the NS5A inhibitor velpatasvir 
and the nucleosidic NS5B inhibitor sofosbuvir received 
approval for all HCV genotypes, for DAA-naïve and 
DAA-experienced patients.(3,4)
However, resistance to DAAs is emerging.(5-7) 
Thus, a subset of DAA-treated patients is experienc-
ing treatment failure, associated with the selection of 
HCV resistance–associated substitutions (RASs).(3-8) 
Furthermore, in certain regions, specific RASs pre- 
exist in up to 50% of individuals.(5,7) Currently, DAA 
combination therapy typically results in cure rates of 
more than 90%, but cure rates might be lower in dif-
ficult-to-treat patient groups.(5,7)
Given a steep increase in the number of individuals 
treated with DAAs, and thus in the absolute num-
ber of individuals with treatment failure, eventually a 
significant number of HCV-infected individuals can 
be expected to harbor DAA-resistant HCV variants. 
Depending on their fitness, resistant variants might 
persist following end of treatment, with the poten-
tial to spread in human populations. RASs at NS3P 
amino acid (aa) position 156, regarded as key media-
tors of resistance for all clinically relevant PIs, were so 
far reported to be associated with high fitness costs, 
which has also hindered in vitro studies.(5,9) In line 
with these findings, 156-RASs were reported not to 
persist long-term following DAA treatment failure.(5,7)
In this study, we initially aimed at carrying out 
PI-resistance profiling using genotype 1-6 infectious 
HCV cell culture systems. Because RASs selected at 
NS3P position 156 were associated with high fitness 
costs, we aimed at developing HCV variants allow-
ing persistence of 156-RASs. Applying genome-wide 
next-generation sequencing (NGS) and substitution 
linkage analysis, we aimed at reconstructing substitu-
tion networks identified outside NS3P, which facili-
tated persistence of highly resistant 156-variants by 
different mechanisms. We further aimed at evaluating 
the effect of pre-existing 156-RASs on DAA combi-
nation treatment. Finally, we investigated the selection 
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of substitutions outside NS3P in patients harboring 
156-RASs at treatment failure.
Materials and Methods
CUltUReD HCV
Recombinants had NS3P of the genotypes(isolates) 
1a(TN),(10) 1b(DH1),(11) 2a( JFH1),(12) 2b(DH8),(13) 
3a(S52),(14) 3a(DBN),(15) 4a(ED43),(14) 5a(SA13),(14) 
and 6a(HK6a)(14,16) (Supporting Fig. S1). The used 
4a(ED43) recombinant was further adapted as des-
cribed in Supporting Fig. S1 (GenBank identifier 
MK600383). Substitutions were engineered by the 
QuikChange Site-Directed Mutagenesis Kit (Agilent). 
NS3P substitutions were numbered relative to the 
NS3P aa sequence; other substitutions were num-
bered relative to the H77 polyprotein sequence 
(GenBank identifier AF009606) unless otherwise 
indicated. The entire HCV sequence of the final DNA 
preparation was confirmed by Sanger sequencing 
(Macrogen).
HUH7.5 Cell CUltURe
Cells were cultured as described.(17) Percentage of 
HCV infected cells was determined by immunostain-
ing with anti-NS5A-9E10(12) and anti-Core-C7-50 
(Enzo Life Sciences and Abcam).(10)
The PIs grazoprevir, paritaprevir, glecaprevir (Acme 
Biosciences) and voxilaprevir (Gilead Sciences), NS5A 
inhibitors pibrentasvir, elbasvir and velpatasvir (Acme 
Biosciences), and NS5B inhibitor sofosbuvir (Acme 
Biosciences) were dissolved in DMSO. For induction 
of viral escape, DAA mono or combination treat-
ment was initiated in cultures with 80%-90% HCV-
infected cells and was administered every 2-3  days 
until occurrence of viral escape (initial decrease fol-
lowed by a peak in the percentage of HCV-infected 
cells), control (single positive HCV-infected cells in at 
least six consecutive immunostainings), or suppression 
(absence of HCV-infected cells in at least six consec-
utive immunostainings).
Viral fitness was evaluated by monitoring viral 
spread kinetics and genetic stability. Spread kinetics of 
variants were compared to that of the original viruses 
following transfection of Huh7.5 cells with HCV 
RNA transcripts using Lipofectamine (Invitrogen)(17) 
by immunostainings or by determination of HCV 
infectivity titers.(16) Unless otherwise indicated, per-
sistence of engineered RASs was evaluated by NS3P 
Sanger sequencing of first-passage supernatant virus 
stocks.
In an evolutionary approach to stabilize 156-RASs, 
156-variants were serially passaged, infecting naïve 
Huh7.5 cells with 1  mL supernatant derived from 
the previous passage and initiating treatment with 
64-fold EC50 grazoprevir when about 5% of cells 
were infected. First, six passages under PI treatment 
were carried out, monitoring viral spread kinetics by 
immunostaining. Then six PI-free passages were done 
to investigate the persistence of 156-RASs.
SINgle-CyCle INFeCtIoN 
aSSayS
CD81-deficient S29 cells(18) were transfected as 
described with 10 μg of HCV RNA transcripts using 
5 μL of Lipofectamine.(19) Four hours following trans-
fection, intracellular Core protein concentration was 
determined; 72  hours following transfection, intra-
cellular and extracellular infectivity titers and Core 
protein concentration were determined.(19) HCV 
infectivity titers were determined as described.(16)
pI SeNSItIVIty
PI concentration-response experiments were done 
as described.(16) Briefly, 5  ×  103 cells in 96-well 
plates were infected with NS3P sequence–confirmed 
first-passage virus stocks. One day after infection, PI 
treatment was administered using a range of noncy-
totoxic concentrations in triplicates.(20) Three days 
following infection, immunostaining was carried out; 
counts of HCV infected cells from treated wells were 
related to means of counts from infected, nontreated 
wells. Concentration-response curves and EC50 val-
ues were obtained using GraphPad Prism.(17)
patIeNt HCV SaMpleS
Serum or plasma from genotype 1a–infected 
patients with DAA treatment failure and acquisi-
tion of 156-RASs were obtained from the European 
Resistance Database at the Department of Internal 
Medicine 1, University Hospital Frankfurt/German 
Center for Infection Research, External Partner Site 
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Frankfurt, Germany (patients A, B, D, and E), and 
the National Reference Center for Viral Hepatitis B, 
C and D, Department of Virology, Henri Mondor 
Hospital, Créteil, France (patient C). Treatment-naïve 
patients were followed at Copenhagen University 
Hospital, Hvidovre.(21,22) The study was conducted 
in accordance with the Declaration of Helsinki, and 
approval for the use of patient blood samples and ret-
rospective collection of data for research purposes was 
obtained from the local ethics committees.
SeQUeNCe aNalySIS
Sanger sequencing of amplicons spanning NS3P or 
the complete open reading frame (ORF) is described 
in the Supporting Methods and Supporting Tables 
S1-S4. NGS analysis of the complete ORF, referred 
to as genome-wide NGS, followed the HCV RNA 
extraction, generation of amplicons spanning the 
complete ORF, and library preparation as described 
in the Supporting Methods and Supporting Tables 
S3 and S4.(23,24) Sequencing of long inserts (500-600 
bases) allowed linkage of NS3P substitutions and 
NS3P haplotype reconstruction using LinkGE (see 
Supporting Methods). Genome-wide linkage analysis 
and haplotype reconstruction was based on frequency 
development of single nucleotide polymorphisms 
(SNPs) in serial viral passage and confirmed by phy-
logenetic analysis of subclones of ORF amplicons, 
including ancestral reconstruction (see Supporting 
Methods).
Results
pI ReSIStaNCe pRoFIlINg 
IDeNtIFIeD geNotype-
SpeCIFIC RaS patteRNS aND 
NS3p poSItIoN 156 aS a RaS 
HotSpot
For PI resistance profiling, Huh7.5 cells were 
infected with HCV recombinants with NS3P of gen-
otypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a (Supporting 
Fig. S1), and treated with 1- to 64-fold EC50 of gra-
zoprevir or paritaprevir. For most cultures, an initial 
decrease in the percentage of HCV-infected cells was 
followed by viral escape (Supporting Fig. S2).
In escaped viruses, across PIs and genotypes, NGS 
analysis revealed RAS hotspots at NS3P aa positions 
156 and 168 (Fig. 1A, Supporting Figs. S3-S11). 
However, we also observed PI- and genotype-specific 
selection patterns. For example, under grazoprevir, 
A156T/V/L dominated for genotypes 1a/b, 2a, 3a, 
and 4a; under paritaprevir, in genotype 1a R155K and 
in genotype 2a D168A dominated. Under both PIs, 
genotypes 2b, 5a and 6a did not acquire substitutions 
at position 156, but primarily at position 168, often in 
combination with other NS3P substitutions.
NGS-based NS3P linkage analysis of SNPs 
selected in all escape viruses (Fig. 1B, Supporting 
Figs. S3-S11) and genome-wide NGS of selected 
escape viruses (Supporting Fig. S3B) revealed that the 
complexity of substitution patterns depended on the 
PI concentration. Low PI concentrations selected for 
a variety of NS3P haplotypes and other ORF substi-
tutions outside NS3P. In contrast, high PI concentra-
tions created an evolutionary bottleneck and selected 
for fewer NS3P haplotypes dominated by few specific 
RASs at hotspots described previously and for fewer 
ORF substitutions outside NS3P. For further viral 
population analysis of genome-wide NGS data, see 
the Supporting Results.
eNgINeeReD RaSs at NS3p 
poSItIoN 156 WeRe oNly 
MaINtaINeD FoR geNotype 
3 aND MeDIateD HIgH pI 
ReSIStaNCe
Most of the 49 engineered genotype 1-6 HCV 
variants with identified NS3P substitutions showed 
decreased fitness. Two variants were nonviable, and 
33 variants showed delayed spread kinetics following 
transfection. For 16 variants, the engineered substitu-
tions were not maintained in first passage (Supporting 
Fig. S12). Of the nine genotype 1a/b, 2a, 3a, and 4a 
A156T/V-variants, only the two 3a(DBN) 156-variants 
maintained these RASs. Among the 16 genotype 1a, 
2a/b, 5a, and 6a D168A/E/H/V/Y variants, 10 main-
tained these RASs.
Most of the 30 tested NS3P variants showed 
cross-resistance to grazoprevir and paritaprevir 
(Supporting Fig. S12). The genotype 1a and 5a 
155-variants showed high resistance to paritaprevir 
(up to 70-fold increase in EC50). The genotype 1a, 
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2a/b, 5a, and 6a 168-variants as well as the genotype 
3a 156-variants showed the highest level of resistance 
to both PIs (up to 219-fold and more than 423-fold 
increase in EC50 for 168-variants and 156-variants, 
respectively). Given the low fitness and high resistance 
of 156-variants, we concentrated on developing and 
characterizing viable 156-variants for genotypes 1-3, 
focusing on the 1a(TN), 2a( JFH1), and 3a(DBN) 
full-length viruses, not harboring proteins of different 
genotypes.(10,12,15)
FIg. 1. HCV genotype 1-6 PI escape viruses harbored NS3P RASs with PI concentration-dependent substitution patterns. 
(A) Putative RASs were identified by NGS. NS3P aa positions with putative RASs found in more than 5% of the viral population for at least 
one virus and one PI were included and numbered relative to NS3P of the H77 reference strain; H77 aa residues are specified. •, aa residues 
identical to that of H77; single letter, nonidentical aa residue; letters separated by dash, putative RASs indicated by the original and the mutated 
residues, color coded depending on the PI under which they were selected. For detailed data including NGS, see Supporting Figs. S3-S11. 
(B) NS3P NGS substitution linkage analysis revealed haplotype distributions for 1a(TN), 2a(JFH1), and 3a(DBN) grazoprevir escape 
viruses (Supporting Figs. S3, S5, S8, S14A-C). Haplotypes constituting greater than 2% of the viral population are included in bars; 
haplotypes greater than 5% are highlighted on bars.
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peRSISteNCe oF a156t IN 
geNotype 1a eSCape VIRUSeS 
DepeNDeD oN FURtHeR 
eVolUtIoN UNDeR pI 
tReatMeNt pReSSURe
Although engineered 156-RASs reverted (Suppor-
ting Fig. S12), 156-RASs were found in the poly- 
clonal escape viruses, suggesting stabilization by 
co-selected fitness compensating substitutions. In 
an attempt to propagate 1a(TN) viruses with 156-
RASs, we passaged polyclonal escape viruses with-
out PI treatment, resulting in a progressive reversion 
of A156T, whereas co-selected substitutions did not 
revert, suggesting that the original 1a(TN) had been 
eradicated by PI treatment (Fig. 2A and Supporting 
Fig. S13).
To stabilize 156-RASs and putative compensatory 
substitutions, we passaged 1a(TN) escape variants 
under continued PI treatment pressure. During serial 
passage under grazoprevir, we observed an accelera-
tion of viral spread kinetics; thus, on day 3 follow-
ing infection, 1%, 10%, and 90% of culture cells were 
HCV-infected in first, third, and sixth viral pas-
sage, respectively (data not shown). Following initial 
escape, the major 1a(TN) population carried A156T 
(Fig. 2B). In third and sixth passage under treatment, 
A156T was maintained in more than 90% of viral 
NS3P haplotypes, but additional NS3P substitutions 
emerged and viral populations with Y134C+A156T 
and A156T+D168E dominated. Following discon-
tinuation of PI treatment, A156T showed long-term 
persistence in more than 90% of viruses, mostly 
combined with D168E.
a geNoMe-WIDe SUBStItUtIoN 
NetWoRK MeDIateD 
peRSISteNCe oF a156t IN 
geNotype 1a eSCape VaRIaNtS 
By MUltIple MeCHaNISMS
Engineered 1a(TN)Y134C+A156T showed poor 
spread kinetics and reversion of A156T following 
transfection. 1a(TN)A156T+D168E spread like the 
original 1a(TN); A156T was maintained in first but 
not in third passage, where the NS3 helicase (NS3H) 
substitution V1656A was detected by Sanger sequenc-
ing (data not shown). Thus, the identified NS3P substi-
tutions alone could not mediate persistence of A156T.
Genome-wide NGS revealed that, induced by 
continued drug pressure, several ORF substitutions 
outside NS3P evolved in 1a(TN) escape virus popu-
lations from passage cultures (Supporting Fig. S14A). 
Evolutionary analysis using genome-wide haplotype 
reconstruction based on SNP frequency development 
in serial viral passage suggested several lines of evolu-
tion. The viral population showing the highest preva-
lence at the end of the experiment (nontreated twelfth 
passage) evolved in three consecutive steps, termed 
evolutionary node 1 (N1, with acquisition of A156T, 
NS4BG1824D, NS5BN2651H, and NS5BE2860G), node 2 
(N2, with additional acquisition of NS3HV1656A), and 
node 3 (N3, with additional acquisition of D168E in 
NS3P) (cyan in Fig. 3A). Alternative lines of evolution, 
branching off at N1 (purple in Fig. 3A) and N2 (blue 
in Fig. 3A) resulted in viral populations showing lower 
prevalence at the end of the experiment. Subsequently, 
these lines of evolution were confirmed by analysis of 
subclones of full ORF amplicons (Supporting Results 
and Supporting Fig. S15).
To model the evolution of N3 viruses, we con-
structed five 1a(TN)A156T recombinants: (1) 
three with different combinations of N1 substitu-
tions in NS4B and NS5B, termed 1a(TN)N1-1, 
1a(TN)N1-2, and 1a(TN)N1-3; (2) one containing 
in addition the N2 substitution NS3HV1656A, termed 
1a(TN)N2; and (3) one containing in addition the 
N3 substitution D168E in NS3P termed 1a(TN)N3 
(Fig. 3B). Stepwise addition of these substitutions 
mediated an incremental increase in viral fitness, 
with 1a(TN)N3 showing accelerated spread kinet-
ics and infectivity titers exceeding those of the orig-
inal 1a(TN) by up to 1.2 log10 focus forming units 
per milliliter (Fig. 3C). In contrast to the three 
1a(TN)N1 viruses, A156T persisted in 1a(TN)N2 
and 1a(TN)N3 without acquisition of additional ORF 
substitutions.
In single-cycle infections, allowing evaluation of 
the impact of genetic modifications on individual 
steps of the HCV life cycle,(18) 1a(TN)A156T showed 
decreased levels of intracellular Core protein com-
pared with 1a(TN), indicating decreased replication 
(Fig. 3D).(25) Addition of the node 1 substitutions in 
NS4B and NS5B restored replication, suggested by 
1a(TN)N1-3 reaching intracellular Core levels higher 
than those of 1a(TN). Addition of NS3HV1656A and 
D168E increased assembly of infectious intracellu-
lar viruses, indicated by 1a(TN)N2 and 1a(TN)N3 
Hepatology, Vol. 70, No. 3, 2019 JENSEN, FAHNØE, ET AL.
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reaching higher intracellular infectivity titers than 
1a(TN)N1-3 (Fig. 3D).
To study whether second site substitutions in 
NS3 were sufficient to mediate A156T persistence, 
we engineered 1a(TN) with A156T+NS3HV1656A, 
A156T+D168E+NS3HV1656A, and for comparison, 
NS3HV1656A, all showing lower infectivity titers than 
1a(TN), 1a(TN)N2, and 1a(TN)N3 (Fig. 3E). A156T 
persisted in 1a(TN)A156T+NS3HV1656A and 1a(TN)
A156T+D168E+NS3HV1656A, which both acquired 
NS4BG1824D.
IN geNotype 2a eSCape 
VaRIaNtS, eVolUtIoN 
oF peRSISteNt a156l WaS 
MeDIateD By INItIal 
aCQUISItIoN oF a156V 
aSSoCIateD WItH oRF 
SUBStItUtIoNS
Following initial escape, A156V dominated in 
2a( JFH1) escape viruses, but reverted following passage 
without PI treatment (Fig. 2C and data not shown). 
Following one passage under drug pressure, the major 
2a( JFH1) population carried A156V, whereas a minor 
population carried A156L (Fig. 2D). During subse-
quent passages, first with and then without treatment, 
A156L became the dominant substitution (Fig. 2D 
and Supporting Fig. S14B). Similar observations were 
made in two additional experiments (data not shown). 
In a parallel approach, we transfected and passaged 
engineered 2a( JFH1)A156V. During six passages 
under treatment and in the subsequent three drug-free 
passages, more than 90% of the viral sequences main-
tained A156V, mostly in combination with D168E 
(Fig. 2E and Supporting Fig. S14D); after three further 
drug-free passages, only 79% of viruses maintained 
A156V. In a replicate experiment, the engineered 
156V changed to L (data not shown). We engineered 
2a( JFH1)A156L, which showed spread kinetics and 
infectivity titers comparable to that of 2a( JFH1) and 
maintained A156L through three drug-free passages 
(Supporting Fig. S14E and data not shown). For 
comparison we also engineered 1a(TN)A156L and 
3a(DBN)A156L. Both viruses maintained A156L with-
out drug pressure (Supporting Fig. S14E). Compared 
with the respective original viruses, 3a(DBN)A156L 
showed comparable spread, but 1a(TN)A156L showed 
severely impaired spread kinetics (data not shown).
As observed for 1a(TN) (Supporting Fig. S14A), 
genome-wide NGS showed acquisition of vari-
ous substitutions in the ORF of 2a( JFH1) escape 
viruses acquiring A156V with subsequent transition 
to A156L (Supporting Fig. S14B) and in engineered 
2a( JFH1)A156V passaged under drug pressure 
(Supporting Fig. S14D). In contrast, 3a(DBN) escape 
viruses with A156V, engineered 2a( JFH1)A156L, and 
engineered 3a(DBN)A156L maintained 156-RASs 
with no obvious selection of other ORF substitutions 
(Supporting Fig. S14C,E). 1a(TN)A156L acquired 
NS3HV1656A and NS4BG1824D, also found in passaged 
1a(TN) escape variants (Supporting Fig. S14E).
a156t, a156V, aND a156l RaSs 
CoNFeRReD HIgH ReSIStaNCe 
FoR geNotypeS 1-3 aCRoSS 
ClINICally ReleVaNt pIs
Resistance testing showed that the developed gen-
otype 1-3 recombinants and polyclonal virus stocks 
FIg. 2. Persistence of 156-RASs in HCV genotypes 1a and 2a was facilitated by further evolution under PI treatment. Haplotype 
frequencies were determined by NGS and substitution linkage analysis; haplotypes constituting more than 2% of the viral population are 
included in the bars; haplotypes with A156T/V/L constituting more than 0.5% of the viral population are included in values above the 
bars; haplotypes constituting more than 20% of the viral population are highlighted on the bars. (A) 1a(TN), escaping 64-fold EC50 of 
grazoprevir (64 × esc.; Fig. 1B and Supporting Figs. S2 and S3) was passaged 3 times without treatment; nontreated first and third passage 
(NT1P, NT3P) were analyzed. (B) 1a(TN) escaping 64-fold EC50 of grazoprevir was passaged 6 times under treatment with 64-fold 
EC50 of grazoprevir and subsequently 6 times without treatment; treated third and sixth passage (64 × T3P, 64 × T6P) and nontreated 
ninth and twelfth passage (NT9P, NT12P) were analyzed. (C) 2a(JFH1) escaping 64-fold EC50 of grazoprevir (different experiment 
than in Fig. 1B and Supporting Figs. S2 and S5) was passaged 3 times without treatment; nontreated third passage (NT3P) was analyzed 
(for 64 × esc., NGS was not successful; Sanger sequencing confirmed dominance of A156V). (D) 2a(JFH1) escaping 64-fold EC50 of 
grazoprevir was passaged 6 times under treatment with 64-fold EC50 of grazoprevir and subsequently 6 times without treatment; treated 
first, third, and sixth passage (64 × T1P, 64 × T3P, 64 × T6P) and nontreated ninth and twelfth passage (NT9P, NT12P) were analyzed. 
(E) 2a(JFH1) with engineered A156V, transfected in Huh7.5 cells, and escaping 64-fold EC50 of grazoprevir was passaged as in (D); 
treated third and sixth passage (64 × T3P, 64 × T6P) and nontreated ninth and twelfth passage (NT9P, NT12P) were analyzed.
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FIg. 3. Evolution of a multimechanistic genome-wide substitution network facilitated the persistence of A156T for HCV genotype 1a. 
(A) Genome-wide linkage analysis of coding substitutions evolving in the 1a(TN) population during passage with/without treatment 
(Fig. 2B), based on SNP frequency development in serial viral passage (Supporting Fig. S14A). Abbreviations: N, node (major step 
in evolution). *NS3P linkage analysis confirmed linkage of the indicated substitution to A156T. NS4BG1824D, NS5BN2651H, and 
NS5BE2860G are linked. NS3HV1656A is linked to the substitution groups in blue and cyan, but not in purple. (B) Schematic overview of 
the 1a(TN) genome and engineered 1a(TN) recombinants. (C) Engineered recombinants were transfected in Huh7.5 cells; extracellular 
infectivity titers given as focus forming units per milliliter (FFU/ml) are means of triplicates with SEM. (-) A156T reverted after first 
or (+) persisted after second passage. (D) Engineered recombinants were transfected in CD81-deficient S29-cells. Intracellular (IC) and 
extracellular (EC) Core levels (percentage, relative to Core concentration determined 4 hours following transfection) and intracellular 
infectivity titers (FFU/ml) are means of duplicates; extracellular infectivity titers (FFU/ml) are means of triplicates with SEM. *Single 
determinations. The bar colors in (C) and (D) match the colors of recombinants in (B). 2a(JFH1)-GND (gray checkerboard) and 
2a(JFH1) (gray stripes) are negative and positive controls, respectively. (E) 1a(TN) recombinants with NS3 substitutions engineered as 
indicated in the legend were transfected in Huh7.5 cells in the same experiment as the recombinants in (C); 1a(TN) and 1a(TN)A156T 
are identical in (C) and (E); extracellular infectivity titers (FFU/ml) are means of triplicates with SEM. (-) A156T reverted after first 
or (+) persisted after second passage. Abbreviations: FFU/ml, focus forming units per milliliter; na, not applicable.
Hepatology, September 2019JENSEN, FAHNØE, ET AL.
780
with 156-RASs were highly resistant to grazoprevir 
and paritaprevir (Fig. 4). We recently acquired the PIs 
glecaprevir and voxilaprevir.(20) As previously observed, 
compared with grazoprevir and especially paritaprevir, 
these PIs showed increased efficacy against the orig-
inal genotype 1-3 viruses.(20) However, all tested 
156-variants were highly resistant to glecaprevir and 
voxilaprevir (Fig. 4).
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156-RaSs MeDIateD eSCape 
oF 1a(tN) FRoM tHe 
pIs gleCapReVIR aND 
VoXIlapReVIR
In 1a(TN) viruses escaping from glecaprevir and 
voxilaprevir A156T/V dominated (Supporting Fig. 
S16A,B), without clear PI concentration-dependent 
patterns as observed under grazoprevir and paritapre-
vir (Fig. 1B and Supporting Figs. S3-S11). Genome-
wide NGS of escape viruses demonstrated co-selection 
of node 1 (NS4BG1824D and NS5BN2651H) and node 2 
(NS3HV1656A) substitutions of the previously identi-
fied substitution network (Supporting Fig. S16C).
pRe-eXIStINg a156t 
FaCIlItateD geNotype 1 
eSCape FRoM CoMBINatIoN 
tReatMeNt
We investigated the effect of clinically relevant 
combination treatments with PI/NS5A inhibitor 
(grazoprevir/elbasvir or glecaprevir/pibrentasvir) and 
PI/NS5A inhibitor/NS5B inhibitor (voxilaprevir/ 
velpatasvir/sofosbuvir) on 1a(TN)N3 harboring A156T 
and D168E in NS3P. In contrast to NS5A inhibi-
tor mono-treatments, PI mono-treatments did not 
affect 1a(TN)N3 infection (Fig. 5A-C). Furthermore, 
1a(TN)N3 readily escaped both double treatments 
at concentrations sufficient to control the original 
1a(TN) (Fig. 5A,B). Using similar concentrations, 
triple treatment suppressed 1a(TN) but only controlled 
1a(TN)N3 (Fig. 5C). Double-treatment escape variants 
acquired the NS5A-RASs M28T or Y93H (Fig. 5D). 
Following termination of triple treatment, 1a(TN)N3 
spread and acquired the NS5A-RAS L31V (Fig. 5D).
aNalySIS oF geNotype 1a 
patIeNt ISolateS HaRBoRINg 
156-RaSs at tReatMeNt 
FaIlURe ReVealeD  
Co-SeleCtIoN oF otHeR oRF 
SUBStItUtIoNS
We studied samples from 5 genotype 1a infected 
patients with 156-RASs following treatment failure 
(patients A to E, Fig. 6A-E). In patients B and D 
with A156V, 63.7% and 8.6% of NS3P haplotypes, 
respectively, showed the original sequence, suggesting 
relatively low stability of the viral population harbor-
ing A156V. In contrast, in patient A, A156V, and 
in patients C and E, A156G was found in 100% of 
NS3P haplotypes. At least for patient C, in whom the 
posttreatment sample was obtained several months 
after treatment termination, this suggested a relatively 
high stability of the viral population with A156G. 
Genome-wide NGS of paired samples obtained before 
and after treatment (patients A, B, and C) revealed 
that under treatment various other ORF substitu-
tions were selected, including substitutions selected 
de novo. Analysis of positions mediating persistence of 
A156T in vitro (Fig. 3) revealed de novo substitutions 
at NS3P position 168 in patients B and C. Other 
de novo substitutions localized to NS3H (patients B 
and C), NS4B (patient C), and NS5B (patients A 
and C). NS3HT1475I and NS3HC1551S (patient B) and 
NS3HS1579C (patient C) localized close to NS3HL1464F 
and NS3HV1561I described for 1a(TN) (Fig. 3A, pur-
ple line of evolution) and were likely linked to A156V 
and D168E (Supporting Fig. S17). All posttreatment 
sequences harbored RASs in all DAA targets. For fur-
ther viral population analysis of genome-wide NGS 
data, see the Supporting Results.
FIg. 4. NS3P variants with 156-RASs showed high PI resistance. For 1a(TN) (A), 2a(JFH1) (B), 3a(S52) (C), and 3a(DBN) (D) 
156-variants, PI concentration-response experiments were carried out using grazoprevir, paritaprevir, glecaprevir, and voxilaprevir as 
described in the Materials and Methods section. Fold-resistance values were calculated by relating EC50 of the indicated variants to 
that of the original viruses included in the same experiment; numbers are rounded off. When possible, 156-variants were engineered 
as recombinants (rec) and first-passage virus stocks were used. For 1a(TN)N2 rec, 1a(TN)N3 rec, and 1a(TN)A156T+NS3H rec 
(including NS3HV1656A), second-passage virus stocks were used (Fig. 3). For 3a(S52)A156L rec, 3a(DBN)A156T rec, and 3a(DBN)
A156V rec, NS3P (Supporting Fig. S12), and for 2a(JFH1)A156L rec and 3a(DBN)A156L rec (Supporting Fig. S14E), the complete 
ORF was sequenced. Otherwise, 156-variants were grown as polyclonal virus stocks (pVS) from nontreated first passages (NT1P) or 
from nontreated twelfth passages (NT12P) of viruses from grazoprevir escape experiments (Fig. 2A,B,D,E). Abbreviations: na, not 
applicable; nd, not done. aResults were from a separate experiment in which the EC50s for 1a(TN) were 2 nM (grazoprevir) and 8 nM 
(paritaprevir). bResults were from a separate experiment in which EC50s for 1a(TN) were 1 nM (grazoprevir) and 6 nM (paritaprevir). 
cViruses were not fully inhibited by the highest PI concentration tested; EC50s are estimates given by GraphPad Prism. dViruses were 
not inhibited by at least 50% by the highest PI concentration tested; EC50s could not be estimated.
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Discussion
We elucidated pathways of HCV PI resistance 
in unprecedented detail. PI resistance profiling con-
firmed NS3P position 156 as a hotspot for RASs 
for genotypes 1-4, but not 5 and 6. However, most 
identified 156-RASs had high fitness costs, except 
for genotype 3. For genotypes 1 and 2, persistence of 
156-RASs depended on dynamic co-evolution of multi- 
mechanistic genome-wide substitution networks. We 
developed highly fit genotype 1-3 156-variants show-
ing high resistance to grazoprevir, paritaprevir, gleca-
previr and voxilaprevir, readily escaping from PI/NS5A 
inhibitor combination treatments. In line with our 
in vitro findings, selection of 156-RASs in genotype 
1–infected patients experiencing DAA treatment 
FIg. 5.  Pre-existing A156T facilitated 1a(TN) escape from combination treatment. 1a(TN)N3 harboring A156T and D168E as 
well as the original 1a(TN) were subjected to mono or combination treatment with grazoprevir and elbasvir (A) or glecaprevir and 
pibrentasvir (B) or mono or triple treatment with voxilaprevir, velpatasvir, and sofosbuvir (C) at the indicated fold-EC50 until viral 
escape, control, or suppression occurred (see Materials and Methods section). Viral control occurred for 1a(TN) under double treatment 
and for 1a(TN)N3 under triple treatment. Viral suppression occurred for 1a(TN) under triple treatment. (D) Sanger sequencing of 
DAA targets of escape variants revealed acquisition of additional RASs in NS3P (brown) and NS5A domain I (purple). aThe RAS 
L31V in NS5A was detected following viral spread to most of the culture cells on day 45 (data not shown), following treatment 
termination on day 31.
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failure was accompanied by selection of substitutions 
outside the drug targets.
Although antiviral resistance is a severe pub-
lic health concern, the understanding of underlying 
mechanisms is limited.(26,27) A recently developed 
technique for NGS-based substitution linkage and 
haplotype reconstruction allowed us to explore the 
nature and frequency of PI resistance–associated 
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NS3P haplotypes in unprecedented detail.(20,28) In 
addition, by analyzing viruses longitudinally during 
evolution under drug pressure, we suggest a strat-
egy for genome-wide linkage analysis and haplotype 
reconstruction, which was validated by subclonal anal-
ysis including ancestral reconstruction.
In vitro testing is required for characteriza-
tion of RASs. In constrast to enzyme and replicon 
assays, infectious HCV culture systems allow inves-
tigation of the complete genome and viral life cycle, 
and results obtained in such systems reflect in vivo 
data.(5-11,13-17,20-22,24,25,29,30)
Most previous studies focused on the characteriza-
tion of RASs for genotype 1.(7) While this study used 
genotype 1-6 infectious culture systems for resistance 
profiling of grazoprevir and paritaprevir, selected RASs 
were in general comparable to those previously selected 
in replicons and in patients.(5-8,31-37)
In line with previous findings, we found geno-
type-specific NS3P RAS selection.(25,30) Also, in con-
trast to genotype 3, for genotypes 1 and 2 persistence of 
A156T/V depended on co-selection of genome-wide 
substitution networks. For genotype 2, initial acquisi-
tion of A156V, with high resistance but low fitness, 
relied on co-selection of other ORF substitutions and 
faciliated acquisition of A156L, with increased resis-
tance and high fitness, without dependence on addi-
tional ORF substitutions. For all viruses, acquisition 
of A156L required two nucleotide changes, whereas 
the initial acquisition of A156V and transition from 
A156V to A156L each required one nucleotide change. 
1a(TN) did not acquire A156L, possibly due to a bias 
toward initial acquisition of A156T and the transition 
from A156T to A156L requiring two nucleotide 
changes. Furthermore, in contrast to 2a( JFH1)A156L, 
3a(S52)A156L and 3a(DBN)A156L, 1a(TN)A156L 
showed poor fitness and co-selection of other ORF 
substitutions. In contrast to A156V/T, A156L was to 
our knowledge not described in patients,(5-8) possibly 
because PI-containing DAA combinations available 
until recently were not recommended for treatment of 
genotypes 2 and 3.
Although patients failing DAA combination 
treatment often have RASs in several drug targets, 
NS3P positions 156 and 168 are hotspots for PI 
resistance.(3,5-7) In line with recent findings in repli-
cons and patients,(6) we demonstrated that 156-RASs 
were essential for resistance to glecaprevir and voxila-
previr for genotype 1a (this study and Pham et al.(20)) 
and genotype 3a.(20) In contrast to grazoprevir and 
paritaprevir, no concentration-dependent RAS selec-
tion patterns, including RASs at other NS3P positions 
than at position 156, were observed for glecaprevir and 
voxilaprevir.(20) This suggested that NS3P position 
156 is the only position mediating major resistance to 
these PIs. In accordance with our findings, Ng et al. 
reported that A156T selected under glecaprevir in the 
1a(H77) subgenomic replicon resulted in high resis-
tance and severe reduction in replication efficacy.(38) 
However, fitness-compensating substitutions were not 
identified and effects on viral assembly, as described in 
our study, cannot be studied in replicons. We further 
demonstrated that pre-existing 156-RASs faciliated 
HCV escape from clinically relevant combination 
treatments with selection of double-resistant escape 
variants.
FIg. 6. Analysis of HCV sequences of genotype 1a–infected patients failing DAA treatment and harboring A156G or V. Patients A, 
B, C, D, and E were treated with glecaprevir + piprentasvir (A,D), grazoprevir + elbasvir (B), or paritaprevir + ombitasvir + dasabuvir 
(C,E). Posttreatment samples were obtained at the given month following end of treatment: patient A, 0 months; patient B, 4.8 months; 
patient C, 4.6 months; patient D, 3.1 months; and patient E, information not available. Bar graphs to the left in each panel show 
NS3P haplotype frequencies determined by NGS and substitution linkage analysis before treatment (pre) and after treatment (post). 
Haplotypes constituting more than 2% of the viral population are included in the bars; haplotypes constituting more than 20% of the 
viral population are highlighted in the bars. Patient B had the NS3P RAS Q80K in all haplotypes detected before and after treatment. 
In (A-C), original refers to the pretreatment consensus sequence. In (D), original refers to the consensus sequence without A156V. The 
three line graphs to the right in (A-C) show ORF-wide NGS, revealing SNP frequencies along the ORF. Pre, SNP frequencies in 
pretreatment sequences mapped against their consensus sequence (known RASs occurring in more than 0.5% of reads are specified); 
Post-all, SNP frequencies in posttreatment sequences mapped to the pretreatment consensus sequence (known RASs occurring in 
greater than 20% of reads are specified); Post de novo selection, frequencies of de novo selected SNPs, found in less than 0.5% of reads in 
pretretament sequences, mapped to the pretreatment consensus sequence (all substitutions occurring in greater than 20% of reads are 
specified). Known RASs are indicated in bold for NS3P using relative NS3P numbers (brown), for NS5A using relative NS5A numbers 
(purple), and for NS5B using relative NS5B numbers (orange). Other de novo SNPs outside the drug targets are in regular font (black), 
with numbers relating to the polyprotein of the H77 reference strain (GenBank identifier AF009606).
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Selection of substitutions at positions mediating per-
sistence of A156T in 1a(TN) was neither PI nor HCV 
isolate-specific. Thus, substitutions at these positions 
were co-selected with 156-RASs under grazoprevir, 
glecaprevir, and voxilaprevir in 1a(TN), 1a(HCV1), 
2a( JFH1), 3a(S52), and 3a(DBN) (Supporting Fig. 
S16C) (unpublished data).(20) NS4BG1824D and 
NS5BN2651H, increasing viral replication, might have 
a general fitness-enhancing effect, as they were also 
detected in the 1a(TN) stock used for inoculation 
of initial escape experiments and selected in 1a(TN) 
serially pasaged without treatment (unpublished 
data). NS3HV1656A, mediating A156T persistence and 
increasing assembly of infectious viruses, might medi-
ate interactions between NS3P and NS3H,(39,40) as it 
was not only acquired by 156-escape variants, but also 
by engineered 1a(TN)A156T+D168E and 1a(TN)
A156L, and because NS3HV1656A alone decreased the 
fitness of 1a(TN).
Although position 156 is highly conserved across 
genotypes, observed genotype-specific differences 
regarding selection of 156-RASs might be explained 
by differences at positions of importance for com-
pensation of fitness costs. In 1a(TN), NS3P substi-
tutions H110D, Y134C/H/N, and D168E/G were 
selected under grazoprevir, Y134C and D168E being 
co-selected with A156T. H110D/Y134C/D168Q and 
H110N/Y134T are natural polymorphisms for gen-
otypes 3a and 2a, respectively. In addition, all other 
positions of the identified substitution network in 
NS3H, NS4B, and NS5B showed different aa resi-
dues for genotypes 3a and 2a compared with genotype 
1a (Supporting Fig. S18). Genotype 3a is difficult to 
treat with DAAs, due to its relatively low sensititivy 
to several PIs and NS5A inhibitors.(7,14,16,20,29,41) Our 
work suggests that an additional reason might be its 
greater propensity to develop resistance to PIs and 
sofosbuvir (this study and Ramirez et al.(15)).
Positions of the identified 1a(TN) substitution 
network were highly conserved in genotype 1a ORF 
sequences from databases(42) (Supporting Fig. S18) 
and in 24 treatment-naïve Danish genotype 1a–
infected patients, analyzed by NGS (Supporting Table 
S6). Except at NS5B2651, the original 1a(TN) had the 
most prevalent aa residue; therefore, rare aa residues 
were selected in the substitution network mediating 
A156T persistence.
In databases,(42) only a few sequences with 156-
RASs were available. Most genotype 1a sequences 
with 156-RASs originated from clones from 2 
patients treated for several days with grazoprevir and 
showing fast reversion of 156-RASs following treat-
ment.(43) Given the short treatment duration, it was 
not surprising that there was no indication for sub-
stitutions at positions mediating 156-RAS persistence 
in vitro.
Patterns of resistance in examined isolates acquir-
ing 156-RASs were similar to those observed in vitro. 
For patients with pretreatment and posttreatment 
samples, substitutions were acquired based on pre- 
existing polymorphisms (as for 1a(TN) NS4BG1824D 
and NS5BN2651H) or de novo (as for the other sub-
stitutions of the identified 1a(TN) substitution net-
work). Several de novo selected substitutions localized 
to NS3P position 168 as well as to NS3H, NS4B and 
NS5B, as described in vitro. Some NS3H substitu-
tions localized close to 1a(TN) NS3H substitutions, 
introducing rare aa residues at otherwise highly con-
served positions. Differences between specific substi-
tutions selected in vitro and in vivo might be due to 
clinical isolates acquiring A156G/V, but not A156T, 
or due to 156-RAS stabilizing substitution networks 
being selected under DAA combination treatment but 
not PI monotherapy. Finally, different alternatives for 
156-RAS stabilizing substitution networks appear to 
exist.
Strikingly, the fitness of highly resistant engineered 
genotype 1 and 2 156-variants matched and even 
exceeded the fitness of the original viruses, rendering 
them among the HCV recombinants with the high-
est fitness described so far. We recently made similar 
observations for sofosbuvir-resistant genotype 3a- and 
6a-variants.(15,24) Thus, in contrast to current percep-
tions, resistance might in some cases be associated 
with increased viral fitness.
With the development of highly fit 156-variants 
for the most prevalent HCV genotypes, we have 
overcome a roadblock for the study of 156-RASs, 
including efforts to identify PIs with efficacy against 
156-variants.
We provided evidence that evolution of highly 
fit and stable 156-RAS variants was possible 
through selection of fitness-compensating substi-
tution networks and reduced efficacy of the most 
advanced DAA combination treatments in vitro. 
So far, an excellent correlation has been observed 
between in vitro HCV-resistance studies and clin-
ical data. As the number of patients treated with 
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DAAs is increasing, it might become more likely 
that 156-variants as described in this in vitro study 
are also observed in the clinic, and thus could 
pose a threat to the efficacy of DAA combination 
treatments.
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